<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01344954</url>
  </required_header>
  <id_info>
    <org_study_id>TB-402-006</org_study_id>
    <nct_id>NCT01344954</nct_id>
  </id_info>
  <brief_title>Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery</brief_title>
  <official_title>Single Intravenous Administration of TB-402 for the Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery: A Phase 2b, Multicentre, Randomised, Active-Controlled, Double Blind, Double Dummy, Parallel Group Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ThromboGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioInvent International AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ThromboGenics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of two doses of TB-402
      administered as a single intravenous infusion for the prevention of VTE in subjects
      undergoing total hip replacement surgery.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">May 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of asymptomatic DVT as detected by bilateral venography and symptomatic VTE, i.e. DVT or fatal or non-fatal PE</measure>
    <time_frame>Randomisation to post-operative day 35</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidents of major VTE</measure>
    <time_frame>Randomisation to Post-Operative day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidents of total DVT</measure>
    <time_frame>Randomisation to Post-Operative day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidents of proximal/distal DVT</measure>
    <time_frame>Randomisation to Post-Operative day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidents of pulmonary embolism</measure>
    <time_frame>Randomisation to Post-Operative day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidents of VTE-related death</measure>
    <time_frame>Randomisation to Post-Operative day 35</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidents of Major VTE</measure>
    <time_frame>Randomisation to Post-Operative day 70</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">632</enrollment>
  <condition>Prophylaxis of Venous Thromboembolic Events</condition>
  <arm_group>
    <arm_group_label>25mg TB-402</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>50mg TB-402</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>10mg QD Rivaroxaban</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TB-402</intervention_name>
    <description>Administered intravenously over 10 minutes</description>
    <arm_group_label>25mg TB-402</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Administered orally as a capsule once a day for 35 days</description>
    <arm_group_label>10mg QD Rivaroxaban</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TB-402</intervention_name>
    <description>Administered intravenously over 10 minutes</description>
    <arm_group_label>50mg TB-402</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects aged ≥ 18 years.

          2. Written informed consent.

          3. Willing and able to comply with scheduled visits, treatment plan, laboratory tests and
             other study procedures

        Exclusion Criteria:

          1. Pregnancy at the time of screening.

          2. Indication for anticoagulation other than post-operative thromboprophylaxis.

          3. Active bleeding or high risk of bleeding.

          4. Anticipated continued use of neuraxial catheter after surgery.

          5. Clinical laboratory findings at screening of thrombocytopenia or prolonged aPTT or PT.

          6. Uncontrolled hypertension.

          7. Impaired liver function (transaminase &gt;3 X ULN) or history of hepatic insufficiency.

          8. Creatinine clearance &lt;30 mL/min.

          9. Antiplatelet agents other than low dose aspirin (&lt; 200mg).

         10. The use of intermittent pneumatic compression.

         11. Known hypersensitivity to contrast media or rivaroxaban.

         12. Known drug or alcohol abuse.

         13. Active malignant disease or current cytostatic treatment.

         14. Stroke within the previous month.

         15. Participation in an investigational drug study within the past 30 days or previous
             participation in this study.

         16. Any condition that in the opinion of the investigator would put the subject at
             increased risk from participating in the study or expected inability to comply with
             the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>KRANKENHAUS DES BARMHER.SCHW.Linz</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen GmbH</name>
      <address>
        <city>Wels</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Wien</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopädisches Spital Speising</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZNA Antwerpen Locatie Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHAT of orthopedics, traumatology and surgery &quot;Sv. Pantaleimon &quot; - Pleven Department of Orthopaedics and Traumatology</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Orthopedics, UMHAT &quot;Sv. Georgi&quot;</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Rousse, Department of Orthopaedics</name>
      <address>
        <city>Rousse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;St Anna&quot; AD,Clinic of Orthopaedics and Traumatology</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT 'Tsaritsa Joanna'</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pándy Kálmán Kórház</name>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bács-Kiskun Megyei Önkormányzat Kórháza, Szegedi Tudományegyetem Általános Orvostudományi Karháza</name>
      <address>
        <city>Kecskemét</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tolna Megyei Önkormányzat Balassa János Kórháza</name>
      <address>
        <city>Szekszárd</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Traumatology and Orthopedics Clinic &quot;Adazi&quot;, LTD</name>
      <address>
        <city>Adazi</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ltd &quot;Liepajas regionala slimnica&quot;</name>
      <address>
        <city>Liepāja</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riga 2nd Hospital</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ltd &quot;Vidzemes slimnica&quot;</name>
      <address>
        <city>Valmiera</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diaconessenhuis Leiden</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Orthopedii I Traumatologii</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Szpital w Puszczykowie</name>
      <address>
        <city>Puszczykowo</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of warsaw, Dept of Orthopaedics</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Ortopedii, WIM</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzkie Centrum Ortopedii i Rehabilitacji Narządu Ruchu im. dr Z. Radlińskiego w Łodzi</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Healthcare Institution &quot;City Clinical Hospital No. 3&quot;</name>
      <address>
        <city>Chelabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Healthcare Medical Institution &quot;City Clinical Hospital No. 4&quot;</name>
      <address>
        <city>Orenburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Healthcare Institution: Clinical Hospital #122 named after L.G. Sokolov under the Federal Medical-Biological Agency of Russia</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Healthcare Institution &quot;City Aleksandrovskaya Hospital&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Healthcare Institution &quot;Municipal Multi-Speciality Hospital No. 2&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution &quot;Samara Regional Clinical Hospital n.a. M.I. Kalinin&quot;</name>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Healthcare Institution &quot;Clinical Hospital of Emergency Care n.a. N.V. Soloviov&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Entity &quot;Regional Hospital - Center of Emergency Medical Care and Disaster Medicine&quot; of Cherkasy Regional Council, Department of orthopedy and traumatology</name>
      <address>
        <city>Cherkassy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankіvsk Regional Clinical Hospital MoH Ukraine, Department of ortopedics and traumatology. Department of traumatology, ortopedics and military/emergency surgery of Ivano-Frankіvsk National Medical University</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE &quot;Sytenko Institute of Spine and Joint Pathology, AMS Ukraine&quot;, department of orthopedic arthrology and endoprosthesis replacement</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Entity of Kyiv Regional council &quot;Kyiv Regional Clinical Hospital&quot;, Ortopedy and traumatology center of Public Entity of Kyiv Regional council &quot;Kyiv Regional Clinical Hospital&quot;</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Establishment &quot;Odessa Regional Clinical Hospital&quot;, Department of Orthopedics and Traumatology.</name>
      <address>
        <city>Odessa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Establishment 'City Hospital #9', orthopedy and traumatology department</name>
      <address>
        <city>Sevastopol</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2011</study_first_submitted>
  <study_first_submitted_qc>April 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2011</study_first_posted>
  <last_update_submitted>August 22, 2012</last_update_submitted>
  <last_update_submitted_qc>August 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

